AnGes Inc
TSE:4563
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Petronet LNG Ltd
NSE:PETRONET
|
IN |
AnGes Inc
Research & Development
AnGes Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AnGes Inc
TSE:4563
|
Research & Development
-¥3.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
SanBio Co Ltd
TSE:4592
|
Research & Development
-¥2.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-7%
|
|
|
GNI Group Ltd
TSE:2160
|
Research & Development
-¥3.3B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
|
PeptiDream Inc
TSE:4587
|
Research & Development
-¥4.6B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Research & Development
-¥6.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Research & Development
-¥1.5B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
AnGes Inc
Glance View
AnGes, Inc. engages in the research and development of gene-based medical products. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 131 full-time employees. The company went IPO on 2002-09-25. The firm is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
See Also
What is AnGes Inc's Research & Development?
Research & Development
-3.5B
JPY
Based on the financial report for Dec 31, 2025, AnGes Inc's Research & Development amounts to -3.5B JPY.
What is AnGes Inc's Research & Development growth rate?
Research & Development CAGR 10Y
0%
Over the last year, the Research & Development growth was 6%. The average annual Research & Development growth rates for AnGes Inc have been 31% over the past three years , 1% over the past five years .
